

# Cardio Policy:

## Myocardial Perfusion Imaging-Exercise Nuclear Stress Testing

<b>POLICY NUMBER</b> UM CARDIO_1084	<b>SUBJECT</b> Myocardial Perfusion Imaging-Exercise Nuclear Stress Testing		<b>DEPT/PROGRAM</b> UM Dept	<b>PAGE 1 OF 6</b>
<b>DATES COMMITTEE REVIEWED</b> 04/01/11, 08/25/11, 11/07/12, 03/10/14, 05/21/14, 05/17/15, 08/12/15, 11/23/16, 12/21/16, 10/10/17, 09/17/18, 02/13/19, 02/21/19, 05/08/19, 07/24/19, 12/11/19, 05/13/20, 01/13/21, 03/10/21, 05/12/21, 07/14/21, 08/12/21, 07/13/22, 02/01/23, 05/10/23, 12/20/23	<b>APPROVAL DATE</b> December 20, 2023	<b>EFFECTIVE DATE</b> December 22, 2023	<b>COMMITTEE APPROVAL DATES</b> 04/01/11, 08/25/11, 11/07/12, 03/10/14, 05/21/14, 05/17/15, 08/12/15, 11/23/16, 12/21/16, 10/10/17, 09/17/18, 02/13/19, 02/21/19, 05/08/19, 07/24/19, 12/11/19, 05/13/20, 01/13/21, 03/10/21, 05/12/21, 07/14/21, 08/12/21, 07/13/22, 02/01/23, 05/10/23, 12/20/23	
<b>PRIMARY BUSINESS OWNER: UM</b>		<b>COMMITTEE/BOARD APPROVAL</b> Utilization Management Committee		
<b>URAC STANDARDS</b> HUM v8: UM 1-2; UM 2-1	<b>NCQA STANDARDS</b> UM 2		<b>ADDITIONAL AREAS OF IMPACT</b>	
<b>CMS REQUIREMENTS</b>	<b>STATE/FEDERAL REQUIREMENTS</b>		<b>APPLICABLE LINES OF BUSINESS</b> Commercial, Exchange, Medicaid	

### I. PURPOSE

Indications for determining medical necessity for myocardial perfusion imaging (MPI).

### II. DEFINITIONS

Myocardial perfusion imaging is used primarily for the evaluation of coronary artery disease and determining prognosis. Myocardial perfusion imaging is a cardiac radionuclide imaging procedure that evaluates blood flow to the cardiac muscle during rest or stress. Stress may be provided by exercise or with pharmacologic agents. A variety of radionuclides may be used, including Technetium tc-99M sestamibi, thallium201 and Technetiumtc-99M tetrofosmin.

For those patients who are unable to complete the exercise protocol without achieving 75-100% of predicted maximal heart rate, a pharmacological nuclear stress test is recommended. This testing method uses a drug to mimic the response of the cardiovascular system to exercise. Adenosine, Persantine, Dobutamine, or Regadenoson are vasodilators used in pharmacological nuclear stress testing. A gamma camera is used to record images in planar or tomographic (single photon emission computed tomography, SPECT) projections.

High global CAD risk is defined as 10-year CAD risk of greater than 20%. CAD equivalents (e.g., DM, PAD) can also define high risk.

10 year CAD risk (%) is defined based on the risk factors- Sex, Age, Race, Total Cholesterol, HDL-Cholesterol, Systolic Blood Pressure, and Treatment for High Blood Pressure, Diabetes Mellitus, and Smoker.

An appropriate diagnostic or therapeutic procedure is one in which the expected clinical benefit exceeds the risks or negative consequences of the procedure by a sufficiently wide margin such that the procedure is generally considered acceptable or reasonable care. The ultimate objective of AUC is to improve patient care and health outcomes in a cost-effective manner but is not intended to ignore ambiguity and nuance intrinsic to clinical decision making.

Appropriate Care - Median Score 7-9

May be Appropriate Care - Median Score 4-6

Rarely Appropriate Care - Median Score 1-3

Guideline directed medical therapy (GDMT) are outlined by joint American College of Cardiology (ACC)/American Heart Association (AHA) in cardiovascular clinical practice guidelines as Class I recommendation. These are maximally tolerated medications for a cardiovascular condition, when prescribed, have shown to improve healthcare outcomes such as survival along with significant reduction in major adverse cardiovascular events and hospitalization. For all recommended drug treatment regimens, the prescriber should confirm the dosage with product insert material and carefully evaluate for contraindications and interactions<sup>1,2,3,4,11,12,13,14,15,16</sup>.

### III. POLICY

#### Indications for approving a request for medical necessity are:

- A. Evaluation of a patient that has chest pain, other symptoms, or signs suggestive of coronary artery disease, and the patient has an abnormal baseline EKG (RBBB, LBBB, IVCD, LVH, Atrial fibrillation, marked resting ST segment changes) or is on a cardiac glycoside (Digoxin) or other medication which would make interpretation of a standard exercise test inaccurate and without an imaging stress test performed within the last 6 months. **(AUC Score 8)**<sup>1,2,3,4,5,6</sup>
- B. Evaluation of a patient who has symptoms suggestive of angina (chest pain, shortness of breath, dyspnea on exertion) who represents a high-risk for having ASCAD based on cardiac risk factors and possibly with a normal EKG. **(AUC Score 8)**<sup>1,2,4,5,6,6</sup>
- C. Evaluation of a patient that has an abnormal or recent non-diagnostic standard exercise test (i.e., unable to reach 75-100% of their age predicted maximal heart rate by physiologic exercise) or has ventricular wall motion abnormality recently demonstrated by another imaging modality and myocardial perfusion imaging is being performed to determine if the patient has myocardial ischemia. No imaging stress test within the last 6 months. **(AUC Score 8)**<sup>1,2,3,4,5,6</sup>
- D. Evaluation of a patient that has known coronary artery disease (or recent myocardial infarction) and myocardial perfusion imaging is being done to determine the functional significance of/or the extent of myocardial ischemia (or scar) resulting from coronary artery disease or to assess myocardial viability and on maximally tolerated GDMT. No prior imaging stress test within the last 3 months. **(AUC Score 9)**<sup>1,2,3,4,5,6,12,13,14,15,16,17</sup>
- E. Testing is being performed to evaluate a patient with known or suspected exercise induced arrhythmias, sustained VT, frequent PVC's, syncope and prior to initiation of antiarrhythmic

therapy in high global CAD risk patients. No imaging stress test within the last 6 months. **(AUC Score 7)**<sup>1,2,3,4,5,6</sup>

- F. Asymptomatic Patient or has stable symptoms, with a high global CAD risk and prior Coronary Calcium Agatston Score between 100-400 **(AUC Score 7)** or with Agatston Score greater than 400 **(AUC Score 8)**<sup>1,2,3,4,5,6</sup>, regardless of risk factors, may be appropriate to follow -up with MPI with no imaging stress test within the last 12 months.
- G. Testing in a symptomatic patient with abnormal Coronary Calcium Agatston Score greater than 100 is appropriate and no imaging stress test within the last 6 months. **(AUC Score 7)**<sup>1,2,4,5,6</sup>
- H. Testing in a patient with non-diagnostic (prior less than 90days) Coronary Computed Tomography Angiography results and there is concern for obstructive CAD is appropriate. No imaging stress test within the last 12 months. **(AUC Score 7)**<sup>1,2,3,4,5,6</sup>
- I. Follow up testing in a patient with new or worsening symptoms with abnormal Coronary Calcium Agatston Score greater than 100 is appropriate. No imaging stress test done within the last 3 months. **(AUC Score 8)**<sup>1,2,4,5,6,6</sup>
- J. Stress Imaging is appropriate in a patient who has recently undergone cardiovascular intervention (CABG or PCI) to evaluate the effectiveness of the intervention an on maximally tolerated GDMT. No imaging stress test done within the last 3 months. **(AUC Score 7)**<sup>1,2,3,4,5,6,12,13,14,15,16,17</sup>
- K. Evaluation with a nuclear stress test may be considered in an asymptomatic patient who has had CABG greater than or equal to 5 years and with stress test performed greater than or equal to 2 years **(AUC Score 7)** or had PCI greater than or equal to 3 years with stress test performed greater than or equal to 2 years and on maximally tolerated GDMT. **(AUC Score 6)**<sup>1,2,3,4,5,6,12,13,14,15,16,17</sup>
- L. Evaluation of a patient with known CAD or who had PCI or CABG and has developed new signs and symptoms suggestive of progression of coronary artery disease and on maximally tolerated GDMT. No imaging stress test within the last 6 months **(AUC Score 8)**<sup>1,2,3,4,5,6,12,13,14,15,16,17</sup>
- M. Evaluation of a patient that has developed congestive heart failure and a silent MI is suspected. No imaging stress test within the last 3 months. **(AUC Score 8)**<sup>1,2,3,4,5,6</sup>
- N. Evaluation of a patient that has a ventricular wall motion abnormality demonstrated by another imaging modality and perfusion imaging is needed to further evaluate the abnormality. No imaging stress test within the last 6 months. **(AUC Score 8)**<sup>1,2,3,4,5,6</sup>
- O. Evaluation of a patient that has severe peripheral vascular disease and is a candidate for peripheral vascular reperfusion by PTA or bypass surgery and myocardial perfusion imaging is being done pre-operatively because there is a concern of possible significant coronary artery disease. No imaging stress test within the last 12 months **(AUC Score 8)**<sup>1,2,3,4,5,6</sup>
- P. Preoperative evaluation of cardiac risk for noncardiac surgery (thoracic, major abdominal or for organ transplant) in patients with significant moderate to high-risk for cardiac disease and no imaging stress test within the last 6 months. **(AUC Score 8)**<sup>1,2,3,4,5,6,8,9,10,11</sup>
- Q. Dual Isotope Imaging can be used to assess myocardial viability and should be considered in patients with prior MI or heart failure only and are on maximally tolerated GDMT. No imaging stress test within the last 12 months. **(AUC Score 7)**<sup>1,2,3,4,5,6,12,13,14,15,16,17</sup>
- R. Patient with coronary artery anomaly (repaired or unrepaired) and no imaging stress test within the last 12 months. **(AUC Score 8)**<sup>1,2,3,4,5,6</sup>

- S. Exercise MPI is indicated in patient who is asymptomatic but has an abnormal EKG that is suggestive for ischemia or another acute cardiac event, and who can exercise. **(AUC Score 7)**<sup>1,2,3,4,5,6</sup>
- T. Apart from the specific scenarios indicated above, stress testing of asymptomatic individuals is reasonable when there are other signs of cardiac pathology e.g., new EKG abnormalities, new wall motion abnormalities on an echo, or a new decrease in LVEF as detected by another modality. **(AUC Score 7)**<sup>1,2,3,4,5,6</sup>
- U. Please refer to *UM\_1175 Perioperative Cardiovascular Evaluation Before Surgery* and *UM\_1119 Pharmacological Nuclear Stress Test and Myocardial Perfusion Imaging* if a request is received for pre- operative cardiac clearance prior to noncardiac and cardiovascular related surgery.

**Limitations:**

- A. Exercise MPI is not routinely indicated in an asymptomatic patient with high global CAD risk, with interpretable EKG and is able to exercise as part of CAD risk assessment.
- B. Before MPI-Exercise Nuclear Stress Testing can be considered in a patient with CAD following must be considered: Predicted or observed lack of adequate response to maximally tolerated GDMT<sup>1,2,3,4,5,12,13,14,15,16,17</sup>
- C. Requests for services that are part of a surveillance protocol for patients who are involved in a clinical trial are considered out of scope (OOS) for New Century Health and cannot be reviewed.

**IV. PROCEDURE**

- A. To review a request for medical necessity, the following items must be submitted for review:
  1. Progress notes that prompted request
  2. Recent EKG (within 10 days), if available
  3. Most recent stress test
  4. Most recent echocardiogram (if applicable)
- B. Primary codes appropriate for this service:
  - 78451, 78452, 78453, 78454, 78466, 78468, 78469 - (Myocardial Perfusion Imaging)
  - 93015 – Cardiovascular Stress test (Supervision, Tracing, Interpretation and Report)
  - 93016 (Supervision only), 93017 (Tracing only), 93018 (Interpretation and Report only)
 Medication codes: A9505/A9502/A9500, J1245/J0153/J2785  
 CPT codes for Dual Isotope: A9505, A9502 or A9505, A9500

**V. APPROVAL AUTHORITY**

- A. Review – Utilization Management Department
- B. Final Approval – Utilization Management Committee

**VI. ATTACHMENTS**

- A. None

**VII. REFERENCES**

1. Centers for Medicare and Medicaid Services. Florida. Local Coverage Determination (LCD) (L38396). Cardiology – non-emergent outpatient testing: exercise stress test, stress echo, MPI SPECT, and cardiac PET. Retrieved from <https://www.cms.gov> [Accessed December 19, 2023].
2. Centers for Medicare and Medicaid Services. Illinois. Local Coverage Determination (LCD) (L33560). Cardiology – non-emergent outpatient testing: exercise stress test, stress echo, MPI SPECT, and cardiac PET. Retrieved from <https://www.cms.gov> [Accessed December 19, 2023].
3. Brindis RG, Douglas PS, Hendel RC, et al. ACCF/ASNC appropriateness criteria for single-photon emission computed tomography myocardial perfusion imaging (SPECT MPI): a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group and the American Society of Nuclear Cardiology endorsed by the American Heart Association. *Journal of the American College of Cardiology*. Oct 2005, Volume 46, Issue 8, Pages 1587- 605.
4. Hendel RC, et al. ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 Appropriate Use Criteria for Cardiac Radionuclide Imaging: A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine. *Journal of the American College of Cardiology*. June 2009, Volume 53, Issue 23, Pages 2201-29.
5. Wolk MJ, et al. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 Multimodality Appropriate Use Criteria for the Detection and Risk Assessment of Stable Ischemic Heart Disease A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. *Journal of the American College of Cardiology*.
6. Robert C. Hendel MD, FACC, FAHA, FASNC, et al. Appropriate use of cardiovascular technology: 2013 ACCF appropriate use criteria methodology update: a report of the American College of Cardiology Foundation appropriate use criteria task force. *Journal of the American College of Cardiology*. March 2013, Volume 61, Issue 12, Pages 1305-1317.
7. NCQA UM 2023 Standards and Elements.
8. Pre-Renal Transplant Risk Stratification. *J Am Coll Cardiol Img*. 2018 Jun, 11 (6) 855–858. <https://doi.org/10.1016/j.jcmg.2017.08.001>
9. DeBolle SA, Ochieng IA, Saha AK, Sung RS. Evaluation of the Effectiveness of Screening for Iliac Arterial Calcification in Kidney Transplant Candidates. *Ann Transplant*. 2020 Sep 15;25:e922178. doi: 10.12659/AOT.922178. PMID: 32929057; PMCID: PMC7518019.
10. Chadban, Steven J. BMed, PhD1Gregory A. MD, MSc15,\* . KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. *Transplantation: April 2020 - Volume 104 - Issue 4S1 - p S11-S103*
11. Martin, P., DiMartini, A., Feng, S., Brown, R., Jr. and Fallon, M. (2014), Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. *Hepatology*, 59: 1144-1165. <https://doi.org/10.1002/hep.26972>
12. Hideyuki Kawashima, et.al. Impact of Optimal Medical Therapy on 10-Year Mortality After Coronary Revascularization. On behalf of the SYNTAX Extended Survival Investigators. *J Am Coll Cardiol*. 2021 Jul, 78 (1) 27–38
13. Amsterdam EA, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-STElevation Acute Coronary Syndromes: a report of the American College of

Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-e228.

14. Levine GN, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients with Coronary Artery Disease. Circulation. 2016 Sep 6;134(10):e123-55.
15. David J. Maron, M.D., Judith S. Hochman, M.D et.al- ISCHEMIA Research Group. Initial Invasive or Conservative Strategy for Stable Coronary Disease- N Engl J Med 2020; 382:1395-407. DOI: 10.1056/NEJMoa1915922.
16. William E. Boden, M.D. et. Al; Optimal Medical Therapy with or without PCI for Stable Coronary Disease. Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation – COURAGE. N Engl J Med 2007; 356:1503-1516. DOI: 10.1056/NEJMoa070829.
17. Pinho-Gomes et al. Guideline Compliance in Contemporary Coronary Revascularization Trials. JACC VOL. 71, NO. 6, 2018. FEBRUARY 13, 2018:591 – 602.